Long-term use of anagrelide in young patients with essential thrombocythemia

Blood

Volumn 97, Issue 4, 2001, Pages 863-866

  Storen, E C ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; HEMOGLOBIN;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BLEEDING; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; HEMOGLOBIN DETERMINATION; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA;

EID: 0035865604     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.4.863     Document Type: Article

References (40)

1. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
2. A clinical update in polycythemia vera and essential thrombocythemia
3. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
4. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
5. Clinical course of essential thrombocythemia in 147 cases
6. No treatment for low-risk thrombocythaemia: Results from a prospective study
7. Major vascular complications in essential thrombocythemia: A study of the predictive factors in a series of 148 patients
8. Essential thrombocythemias: Clinical evolutionary and biological data
9. 9/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages
10. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
11. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea
12. Pipobroman therapy of essential thrombocythemia
13. Efficacy trial of pipobroman in essential thrombocythemia: A study of 24 patients
14. Interferon alpha-2b in the long-term treatment of essential thrombocythemia
15. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia
16. Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia
17. Primary thrombocythaemia treated with busulphan
18. Leukemia and myelodysplasia: Effect of multiple cytotoxic therapy in essential thrombocythemia
19. The treatment of essential thrombocythaemia with radioactive phosphorus
20. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: Are safer drugs available?
21. Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32 - A 15 year review
22. Anagrelide: A new drug for treating thrombocytosis
23. Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients
24. Therapy with anagrelide in patients affected by essential thrombocythemia: Preliminary results
25. Treatment of essential thrombocythemia with anagrelide
26. Treatment of children with anagrelide for thrombocythemia
27. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia
28. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: Treatment experience in 48 patients in Germany
29. The effects of anagrelide on human megakaryocytopoiesis
30. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans
31. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: Mechanism of action, efficacy, toxicity, current indications
32. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment
33. Acquired DNA mutations associated with in vivo hydroxyurea exposure
34. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age
35. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
36. New drugs in essential thrombocythemia and polycythemia vera
37. Ketanserin: A new perspective in posttransplant erythrocytosis?
38. Prognostic and diagnostic value of endogenous erythroid colony formation in essential thrombocythemia
39. Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia
40. Thrombotic complications in essential thrombocythemia with relatively low platelet counts